Fintel reports that on November 18, 2025, B of A Securities maintained coverage of Acumen Pharmaceuticals (NasdaqGS:ABOS) with a Buy recommendation.
Analyst Price Forecast Suggests 335.76% Upside
As of November 17, 2025, the average one-year price target for Acumen Pharmaceuticals is $6.88/share. The forecasts range from a low of $4.04 to a high of $10.50. The average price target represents an increase of 335.76% from its latest reported closing price of $1.58 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Acumen Pharmaceuticals is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.11.
What is the Fund Sentiment?
There are 140 funds or institutions reporting positions in Acumen Pharmaceuticals. This is an decrease of 12 owner(s) or 7.89% in the last quarter. Average portfolio weight of all funds dedicated to ABOS is 0.02%, an increase of 41.25%. Total shares owned by institutions decreased in the last three months by 7.92% to 38,083K shares. 
The put/call ratio of ABOS is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 14,932K shares representing 24.65% ownership of the company. No change in the last quarter.
Sands Capital Ventures holds 3,417K shares representing 5.64% ownership of the company. No change in the last quarter.
Franklin Resources holds 2,305K shares representing 3.81% ownership of the company. In its prior filing, the firm reported owning 3,077K shares , representing a decrease of 33.49%. The firm decreased its portfolio allocation in ABOS by 83.37% over the last quarter.
Knollwood Investment Advisory holds 1,629K shares representing 2.69% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,146K shares representing 1.89% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
